Literature DB >> 28237487

HSP70 inhibitor combined with cisplatin suppresses the cervical cancer proliferation in vitro and transplanted tumor growth: An experimental study.

Jian Liu1, Jing Liu2, Su-Yang Guo2, Hong-Li Liu2, Sheng-Ze Li2.   

Abstract

OBJECTIVE: To study the regulating effect of HSP70 inhibitor (PES) combined with cisplatin on cervical cancer proliferation in vitro and transplanted tumor growth.
METHODS: Cervical cancer Hela cell lines were cultured and divided into control group, cisplatin group, PES group and cisplatin + PES group that were treated with serum-free DMEM, cisplatin with final concentration of 10 μmol/L, PES 20 μmol/L and cisplatin 10 μmol/L combined with PES with 20 μmol/L, respectively; animal models with cervical cancer xenografts were established and divided into control group, cisplatin group, PES group and cisplatin + PES group who received intra-tumor injection of normal saline, 10 μmol/L cisplatin, 20 μmol/L PES as well as 10 μmol/L cisplatin + 20 μmol/L PES, respectively. Cell proliferation activity, transplanted tumor volume and mitochondria apoptosis molecule expression were detected.
RESULTS: Cell viability value and Bcl-2 mRNA expression in cells of cisplatin group, PES group and cisplatin + PES group were significantly lower than those of control group while Bax, Caspase-3 and Caspase-9 mRNA expression in cells were significantly higher than those of control group; transplanted tumor volume and the Bcl-2 mRNA expression in transplanted tumor tissue of cisplatin group, PES group and cisplatin + PES group were significantly lower than those of control group while Bax, Caspase-3 and Caspase-9 mRNA expression in transplanted tumor tissue were significantly higher than those of control group.
CONCLUSIONS: HSP70 inhibitor combined with cisplatin can inhibit cervical cancer cell proliferation in vitro and transplanted tumor growth through mitochondrial apoptosis pathway.
Copyright © 2017 Hainan Medical University. Production and hosting by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cervical cancer; Heat shock protein 70; Mitochondrial apoptosis pathway; Transplanted tumor

Year:  2017        PMID: 28237487     DOI: 10.1016/j.apjtm.2017.01.020

Source DB:  PubMed          Journal:  Asian Pac J Trop Med        ISSN: 1995-7645            Impact factor:   1.226


  5 in total

1.  A Novel Inhibitor of HSP70 Induces Mitochondrial Toxicity and Immune Cell Recruitment in Tumors.

Authors:  Jessica C Leung; Julia I-Ju Leu; Subhasree Basu; Adi Narayana Reddy Poli; Thibaut Barnoud; Joshua L D Parris; Alexandra Indeglia; Tetyana Martynyuk; Madeline Good; Keerthana Gnanapradeepan; Emilio Sanseviero; Rebecca Moeller; Hsin-Yao Tang; Joel Cassel; Andrew V Kossenkov; Qin Liu; David W Speicher; Dmitry I Gabrilovich; Joseph M Salvino; Donna L George; Maureen E Murphy
Journal:  Cancer Res       Date:  2020-10-06       Impact factor: 12.701

2.  Proteomic identification of proteins differentially expressed following overexpression of hTERT (human telomerase reverse transcriptase) in cancer cells.

Authors:  Rishi Kumar Jaiswal; Pramod Kumar; Amod Sharma; Deepak Kumar Mishra; Pramod Kumar Yadava
Journal:  PLoS One       Date:  2017-07-13       Impact factor: 3.240

3.  Metformin inhibits cervical cancer cell proliferation by modulating PI3K/Akt-induced major histocompatibility complex class I-related chain A gene expression.

Authors:  Chenglai Xia; Chang Liu; Zhihong He; Yantao Cai; Jinman Chen
Journal:  J Exp Clin Cancer Res       Date:  2020-07-06

4.  Inducible HSP70 antagonizes cisplatin‑induced cell apoptosis through inhibition of the MAPK signaling pathway in HGC‑27 cells.

Authors:  Lili Sheng; Tuo Tang; Yinhua Liu; Yunfei Ma; Ziqian Wang; Hong Tao; Yao Zhang; Zhilin Qi
Journal:  Int J Mol Med       Date:  2018-07-19       Impact factor: 4.101

5.  HSP70 regulates cell proliferation and apoptosis in actinomycin-D-treated lung cancer cells.

Authors:  Kai Zhang; Ruonan Zhai; Teng Xue; Xiaoyan Xu; Yanan Ren; Mingze Ma; Fengxian Shi; Hang Wang; Na Wang; Fang Zhou
Journal:  Transl Cancer Res       Date:  2020-02       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.